· sı	ubstitute or form 1449A/PTC	· · · · · · · ·		COMPLETE IF KNOWN		
	NFORMATIO		CLOSURE	Application Number	46.5507/9	
	•			Filing Date	10/552362 -	
S	TATEMENT I	BY AP	PLICANT	First Named Inventor		
				Group Art Unit		
	(use as many sh	eeis as n	ecessary)	Examiner Name		
Sheet	1	of	2	Attorney Docket Number	MS0036YP	
						

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY	
					05/30/2000	
			<u> </u>			
			 			
			<u> </u>		·	
			 			
			 			
			+			
			+			
			1			
			<u> </u>			
			1	<u> </u>		
			 			
İ			1			

		-	FOREI	GN PATENT	T DOCUMENTS	
Examiner Initials*	No.		Foreign Patent Documen		Name of Patentee or Applicant	Date of Publication
		Office Number		Kind Code <i>(if known)</i>	of Cited Document	
/KC/	A1	W	O 03/051315 A2		Cosford, et al.	06/26/2003
Examin Signatu	er ire		/Karen Cheng/		Date Consider	red 04/02/2007

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	ibstitute for form 1449B/PTO NFORMATION	DIS	CLOSURE	Application NJC05 RCC OPCT/PTO 03 OCT 2007		
				Filing Date	10/552362	
S	TATEMENT B	Y AP	PLICANI	First Named Inventor		
		.4		Group Art Unit		
	(use as many shee	us as n	ecessary)	Examiner Name	·	
Sheet	2	of	2	Attorney Docket Number	MS0036YP	

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.						
/KC/	A2	Revesz. et al., SAR of 2,6-Diamino-3,5-difluoropyridinyl Substituted Heterocycles as Novel p38 MAP Kinase Inhibitors, Bioorganic & Medicinal Chemistry Letters, 12 (2002) 2109-2112.						
		•						
_								

Examiner Signature	/Karen Cheng/	Date Considered	04/02/2007

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.